The Use Of AMH for the Discrimination of Polycystic and Multicystic Ovaries in Nonhyperandrogenic Patients

NCT ID: NCT01878955

Last Updated: 2018-03-01

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 140 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-02-29
• Study Completion Date: 2018-12-31

Brief Summary

AMH is a member of the transforming growth factor family. It is produced by the granulosa cells from 36th weeks of pregnancy.Ovarian granulosa cells are the only source of the antimüllerian hormone. AMH production continues until response to exogenous FSH occurs and follicles reach 4-6 mm in diameter.The number of follicles in patients with polycystic ovaries are 2-6 times higher than normal women. Serum AMH levels are 2-3 times higher in patients with PCOS. The cause of elevated serum AMH levels in patients with PCOS is unknown. There are data showing elevated serum AMH level is due to the increase in the number of follicles 2-8 mm in diameter. Although there is no precise definition; multicystic ovarian is defined by the presence of more than six follicles 4-9 mm in diameter and mixed morphologically with PCO. PCO and multicystic ovaries are distinguished by the absence of the increase in stroma / volume.The aim of this study is to investigate whether there is a difference of serum AMH levels between patients with PCO or multicystic ovaries. A primary goal is to investigate the usability of AMH as a marker besides ultrasound for discrimination of nonhyperandrogenic patients with PCO or multicystic ovaries.

Detailed Description

It is planned to compare the values of FSH/LH, AMH, and 75 gr OGTT between 20 patients diagnosed as PCOS according to the AES-Rotterdam criteria and 20 patients with multicystic ovarian structure but do not provide the PCOS-D3 criteria. The second purpose of this study is to investigate the mechanism that leads to the elevation of AMH in patients with PCOS, and to reveal the effects of intraovarian paracrine factors,insulin resistance and FSH /LH.

Conditions

Polycystic Ovary Syndrome

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

->6 4-9 mm follicles in bilateral ovaries

Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria

AMH level difference between patient with PCOS and multicystic ovaries.

Intervention Type: GENETIC

Interventions

AMH level difference between patient with PCOS and multicystic ovaries.

Intervention Type: GENETIC

Eligibility Criteria

Inclusion Criteria

• Between the ages of 15-43
• >6 4-9 mm follicles in bilateral ovaries at ultrasonographic examination
• Increased ovarian volume (>10 ml )

Exclusion Criteria

• Hormonal drug users
• Late onset congenital adrenal hyperplasia,androgen secreted ovarian or adrenal tumors

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 43 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Izmir Katip Celebi University

OTHER

Sponsor Role: lead

Responsible Party

Serpil aydoğmuş

Assistant professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Serpil Aydoğmuş, assoc prof

Role: STUDY_DIRECTOR

Izmir Katip Çelebi University

Other Identifiers

AMH-123

Identifier Type: -

Identifier Source: org_study_id